CoChat
Sign Up
Cited by 1,064Diabetes Treatment and ManagementClinical practice guidelines implementationDiabetes Management and Education

Global guideline for type 2 diabetes

Open access
·2014·Diabetes Research and Clinical Practice
DOI 10.1016/j.diabres.2012.10.001
Open this paper in CoChat — free accountOpen PDF

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.diabres.2012.10.001

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Due to its high specificity, urine glucose is advocated by the IDF as a screening test for undiagnosed diabetes in low-resource settings where other procedures are not available.

    “In addition, due to its high specificity, urine glucose is advocated by the IDF as a screening test for undiagnosed diabetes in low-resource settings where other procedures are not available (297).”

    From Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus (2023) · cites this paper as [297]

    The guideline’s screening discussion says urine glucose has high specificity (>98%) and may have a place for detecting undiagnosed diabetes in low-resource settings where other procedures are unavailable. But it also notes low sensitivity (21–64%); “may have a place” is more cautious than saying the IDF advocates it as a screening test. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 152 · Cited by 1,064

Research works printed but not linked: 82

  1. [1]1. Spijkerman AMW, Dekker JM, Nijpels G, et al. Microvascular complications at time of diagnosis of type 2 diabetes are similar among diabetic patients detected by targeted screen- ing and patients newly diagnosed in general practice: the Hoorn screening study. Diabetes Care 2003; 26: 2604-2608.
  2. [7]7. Schneider H, Ehrlich M, Lischinski M, et al. Bewirkte das fl ächendeckende glukosurie-screening der 60er und 70er jahre im Osten Deutschlands tatsächlich den erhofften Prognosevorteil für die frühzeitig entdeckten Diabetiker? Diabetes Stoffwech 1996; 5: 33-38.
  3. [8]8. Colagiuri S, Cull CA, Holman RA. Are lower fasting plasma glucose levels at diagnosis of type 2 diabetes associated with improved outcomes? UKPDS 61. Diabetes Care 2002; 25: 1410-1417.
  4. [10]10. Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. Diabetes Care 2003; 26: 725-731.
  5. [13]13. Report of a World Health Organization Consultation. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Diabetes Res Clin Pract 2011; 93: 299-309.
  6. [14]14. Shojania KG, Ranji SR, McDonald KM, et al. Effects of quality improvement strategies for type 2 diabetes on glycaemic con- trol. JAMA 2006; 296: 427-440.
  7. [15]15. Renders CM, Valk GD, Griffi n SJ, et al. Interventions to improve the management of diabetes in primary care, outpatient, and community settings: a systematic review. Diabetes Care 2001; 24: 821-833.
  8. [17]17. Klonoff DC. Diabetes and telemedicine. Is the technology sound, effective, cost-effective and practical? Diabetes Care 2003; 26: 1626-1628.
  9. [28]28. Mulcahy K, Maryniuk M, Peeples M, et al. Diabetes self-man- agement education core outcome measures. Diabetes Educator 2003; 29: 768-803.
  10. [32]32. Mulcahy K, Maryniuk M, Peeples M, et al. Diabetes self-man- agement education core outcome measures. Diabetes Educator 2003; 29: 768-803.
  11. [41]41. Piette JD, Glasgow RE. Education and home glucose monitoring. In: Gerstein HC, Haynes RB (eds). Evidence based diabetes care. Hamilton, Ontario: BC Decker; 2001: 207-2051.
  12. [46]46. Peyrot M, Rubin R, Funnell M, et al. Access to diabetes self- management education: results of national surveys of patients, educators and physicians. Diabetes Educator 2009; 35: 246-263.
  13. [52]52. Rotheram-Borus MJ, Tomlinson M, Gwegwe M, et al. Diabetes buddies: peer support through a mobile phone buddy system. Diabetes Educator 2012; 38: 357-365.
  14. [54]54. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas 1977; 3: 385-401.
  15. [60]60. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http://www.diabetes.ca.
  16. [66]66. Li C, Ford ES, Zhao G, et al. Prevalence and correlates of depression among U.S. adults with diabetes. The behavioral risk factor surveillance system 2006. Diab Res Clin Pract 2009; 83: 268-279.
  17. [68]68. van Bastelaar KM, Pouwer F, Cuijpers P, et al. Web-based depression treatment for type 1 and type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2011; 34: 320-325.
  18. [69]69. Lustman PJ, Griffi th LS, Freedland KE, et al. Cognitive behavior therapy for depression in type 2 diabetes mellitus: a randomized controlled trial. Arch Intern Med 1998; 129: 613-621.
  19. [73]73. Kim C, Bullard KM, Herman WH, et al. Association between iron defi ciency and A1C levels among adults without diabetes in the National Health and Nutrition Examination Survey, 1999-2006. Diabetes Care 2010; 33: 780-785.
  20. [74]74. Border DK, Round RA, Mason CL, et al. Raised fetal haemoglobin in patients with diabetes and other coexisting illnesses. Diabet Med 2011; 28: S164 P438.
  21. [75]75. Cappellini M-D, Cohen A, Eleftheriou A, et al. Guidelines for the clinical management of thalassaemia 2nd edition revised 2008. Cyprus: Thalassaemia International Federation; 2008.
  22. [76]76. Vandewiele A, Genbrugge K, Delanghe J. Spuriously high HbA1c due to the presence of haemoglobin Raleigh: a case report and review of the literature. J Acta Clin Belg 2010; 65: 336-340
  23. [77]77. Misra S, Hancock MR, Roper D, et al. Rare, 'fast' haemoglobin variants may interfere with HbA1c measurement using ion exchange high performance liquid chromatography: implications for diagnosis of diabetes. EASD 2012; Abstract No: A-1091. In press.
  24. [78]78. Mittman N, Desiraju B, Fazil I, et al. Serum fructosamine versus glycosylated hemoglobin as an index of glycemic control, hospitalization, and infection in diabetic hemodialysis patients. Kidney Int Suppl 2010; 117: S41-S45.
  25. [79]79. Manley SE, Gomes AN, McKnight JA, et al. When fructosamine results do not refl ect glycaemic control indicated by other markers? Diabet Med 2009; 26: S154 P390.
  26. [81]81. The Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group, Tamborlane WV, Beck RW, Bode BW, Buckingham B, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 2008; 359: 1464-1476.
  27. [82]82. Harman-Boehm I. Continuous glucose monitoring in type 2 diabetes. Diabetes Res Clin Pract 2008; 82: S118-S121.
  28. [83]83. American Diabetes Association. Bedside blood glucose monitoring in hospitals. Diabetes Care 2004; 27: S104. s
  29. [85]85. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clini- cal practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http:// www.diabetes.ca.
  30. [89]89. Report of a World Health Organization Consultation. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Diabetes Res Clin Pract 2011; 93: 299-309.
  31. [97]97. Hanas R, John G. 2010 consensus statement on the worldwide standardization of the hemoglobin A(1c) measurement. Diabetes Res Clin Pr 2010; 90: 228-230.
  32. [101]101. Manley SE, Moore S, Smith JM, et al. When HbA1c for a patient does not refl ect glycaemic control indicated by plasma glucose monitoring. Diabet Med 2008; 25: 256. e s
  33. [102]102. Bot S, Davis TME, Davis WA, et al. Self-monitoring of blood glucose in type 2 diabetes: an inter-country comparison. Diabetes Res Clin Pract 2008; 82: e15-e18.
  34. [105]105. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clini- cal practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http:// www.diabetes.ca.
  35. [106]106. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2012; 35: S11-S63.
  36. [108]108. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and car- diovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
  37. [109]109. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin thera- py prevents the progression of diabetic microvascular compli- cations in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
  38. [110]110. Towfi gh A, Romanova M, Weinreb JE, et al. Self-monitoring of blood glucose levels in patients with type 2 diabetes mellitus not taking insulin: a meta-analysis. Am J Manag Care 2008; 14: 468-475.
  39. [111]111. Karter AJ, Parker MM, Moffet HH, et al. Longitudinal study of new and prevalent use of self-monitoring of blood glucose. Diabetes Care 2006; 29: 1757-1763.
  40. [112]112. Davis WA, Bruce DG, Davis ME. Does self-monitoring of blood glucose improve outcome in type 2 diabetes? The Fremantle diabetes study. Diabetologia 2007; 50: 510-515.
  41. [113]113. Farmer A, Wade A, Goyder E, et al. Impact of self monitoring of blood glucose in the management of patients with non- insulin treated diabetes: open parallel group randomised trial. BMJ 2007; 335: 132.
  42. [114]114. Simon J, Gray A, Clarke P, et al. Cost effectiveness of self monitoring of blood glucose in patients with non-insulin treated type 2 diabetes: economic evaluation of data from the DiGEM trial. BMJ 2008; 336: 1177-1180.
  43. [115]115. O'Kane MJ, Bunting B, Copeland M, et al, the ESMON Study Group. Effi cacy of self monitoring of blood glucose in patients with newly diagnosed type 2 diabetes (ESMON study): randomised controlled trial. BMJ 2008; 336: 1174-1177.
  44. [116]116. Barnett AH, Krentz AJ, Strojek K, et al. The effi cacy of self- monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modifi ed release-based regimen. A multicentre, randomized, parallel- group, 6-month evaluation (DINAMIC 1 study). Diabetes Obes Metab 2008; 10: 1239-1247.
  45. [121]121. Bruno G, De Micheli A, Frontoni S, et al, Società Italiana di Diabetologia-Associazione Medici Diabetologi (SID-AMD) working group on the Standards of Care for Diabetes. Highlights from "Italian Standards of care for Diabetes Mellitus 2009- 2010". Nutr Metab Cardiovasc Dis 2011; 21: 302-314.
  46. [128]128. van de Laar FA, Lucassen PL, Akkermans RP, et al. α-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 2005; 28: 154-163.
  47. [133]133. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 2007; 298: 1189-1195.
  48. [135]135. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive (PROspective pioglitAzone Clinical Trial in macrovascular Events): a randomized controlled trial. Lancet 2005; 366: 1279-1289.
  49. [136]136. Rosenstock J, Sugimoto D, Strange P, et al. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care 2006; 29: 554-559.
  50. [140]140. Giugliano D, Maiorino MI, Bellastela G, et al. Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: a systematic review. Diab Res Clin Pr 2011; 92: 1-10.
  51. [142]142. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin- dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103-117.
  52. [143]143. Raskin P, Bode BW, Marks JB, et al. Continuous subcutaneous insulin therapy and multiple daily injection therapy are equally effective in type 2 diabetes. Diabetes Care 2003; 26: 2598-2603. clinical guideline 87. London: Royal College of Physicians; 2009. http://www.nice.org.uk/nicemedia/pdf/ CG87NICEGuideline.pdf.
  53. [144]144. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clini- cal practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http:// www.diabetes.ca.
  54. [147]147. Bangalore S, Kumar S, Lobach I, et al. Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glu- cose: observations from traditional and bayesian random- effects meta-analyses of randomized trials. Circulation 2011; 123: 2799-2810.
  55. [155]155. ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin versus chlorthalidone. The antihypertensive and lipid- lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2000; 283: 1967-1975.
  56. [171]171. Calvin AD, Aggarwal NR, Murad MH, et al. Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 2009; 32: 2300-2306.
  57. [178]178. Stevens R, Kothari V, Adler AI, et al. UKPDS 56: the UKPDS risk engine: a model for the risk of coronary heart disease in type 2 diabetes. Clin Sci 2001; 101: 671-679. www.dtu.ox.ac.uk/ index.php?maindoc=/riskengine.
  58. [183]183. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clini- cal practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http:// www.diabetes.ca.
  59. [191]191. Kohner EM, Aldington SJ, Stratton IM, et al. United Kingdom Prospective Diabetes Study 30: diabetic retinopathy at diagno- sis of non-insulin-dependent diabetes mellitus and associat- ed risk factors. Arch Ophthalmol 1998; 116: 297-303.
  60. [192]192. Klein R, Klein BEK, Moss SE, et al. The Wisconsin epidemio- logic study of diabetic retinopathy IV. Diabetic macular edema. Ophthalmology 1984; 91: 1464-1474.
  61. [196]196. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http://www.diabetes.ca.
  62. [199]199. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
  63. [203]203. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383-393.
  64. [205]205. Bakker K, Apelqvist J, Schaper NC, et al, the International Working Group on the Diabetic Foot Editorial Board. Practical guidelines on the management and prevention of the diabetic foot 2011. Diabetes Metab Res Rev 2012; 28: 225-231.
  65. [206]206. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2012; 35: S11-S63.
  66. [207]207. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clini- cal practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http:// www.diabetes.ca.
  67. [210]210. Schaper NC, Andros G, Apelqvist J, et al. Diagnosis and treat- ment of peripheral arterial disease in diabetic patients with a foot ulcer. A progress report of the International Working Group on the Diabetic Foot. Diabetes Metab Res Rev 2012; 28: 218-224.
  68. [212]212. Boulton AJM, Malik RA, Arezzo JC, et al. Diabetic somatic neuropathies (technical review). Diabetes Care 2004; 27: 1458-1486.
  69. [213]213. Vinik AI, Maser RE, Mitchell B, et al. Diabetic autonomic neuropathy: a technical review. Diabetes Care 2003; 26: 1553-1579.
  70. [214]214. Moore M. Nutrition therapy for diabetic gastropathy. In: Franz MJ, Evert AB (eds). American Diabetes Association guide to nutrition therapy for diabetes. 2nd ed. Alexandria, VA: American Diabetes Association; 2012: 355-369.
  71. [216]216. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clini- cal practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http:// www.diabetes.ca.
  72. [218]218. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2012; 35: S11-S63.
  73. [220]220. Freeman R, Durso-Decruz E, Emir B. Effi cacy safety, and toler- ability of pregabalin treatment for painful diabetic peripheral neuropathy: fi ndings from seven randomized, controlled tri- als across a range of doses. Diabetes Care 2008; 31: 1448-1454.
  74. [222]222. Dyck PJ, Kratz KM, Karnes JL, et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy, and nephropathy in a population-based cohort: the Rochester Diabetic Neuropathy Study. Neurology 1993; 43: 817-824. s
  75. [226]226. Sinclair AJ, Paolisso G, Castro M, et al, the European Diabetes Working Party for Older People. European Diabetes Working Party for Older People 2011 clinical guidelines for type 2 dia- betes mellitus. Executive summary. Diabetes Metab 2011; 37: S27-S38.
  76. [227]227. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clini- cal practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http:// www.diabetes.ca.
  77. [233]233. Nelson ME, Rejeski WJ, Blair SN, et al. Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. Circulation 2007; 116: 1094-1105.
  78. [234]234. Biessels GJ, Staekenborg S, Brunner E, et al. Risk of dementia in diabetes -a systematic review. Lancet Neurol 2006; 5: 64-74.
  79. [236]236. Gonzalez J, Safren S, Cagliero E, et al. Depression, self-care, and medication adherence in type 2 diabetes: relationships across the full range of symptom severity. Diabetes Care 2007; 30: 2222-2227.
  80. [240]240. Pratley RE, Rosenstock J, Pi-Sunyer FX, et al. Management of type 2 diabetes in treatment-naive elderly patients: benefi ts and risks of vildagliptin monotherapy. Diabetes Care 2007; 30: 3017-3022.
  81. [243]243. e s 1. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2012; 35: S11-S63.
  82. [245]245. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Canadian Diabetes Association 2008 clini- cal practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2008; 32: S95-S98. http:// www.diabetes.ca.

Venue
Diabetes Research and Clinical Practice
Publisher
Elsevier BV
Published
2014-04
Volume
104
Issue
1
Pages
1-52
ISSN
0168-8227 (ISSN-L)
DOI
10.1016/j.diabres.2012.10.001
OpenAlex
W2527670279
Semantic Scholar
435a35b005b9f85059ee963f57f3ddd376f4d381
Cited by
1,064
References
152
Citations by year
2026: 12 · 2025: 20 · 2024: 27 · 2023: 33 · 2022: 39 · 2021: 44 · 2020: 64 · 2019: 85 · 2018: 74 · 2017: 81 · 2016: 85 · 2015: 84 · 2014: 90 · 2013: 55 · 2012: 44
FWCI
91.21
Type
journal article
Language
en
Open access
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Diabetes Research and Clinical Practice (publishedVersion)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • Repositorio Institucional (Pontificia Universidad Javeriana) (publishedVersion, cc-by-nc)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
  • CONICET Digital (CONICET) (submittedVersion, cc-by-nc-sa)
  • Research Publications (Maastricht University) (submittedVersion)
Funders
  • Eli Lilly and Company
  • Sanofi
  • McGill University
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
Keywords
type 2 diabetes, diabetes management, levels of care, cost-effectiveness, resource-limited settings, evidence-based care, diabetes care standards, International Diabetes Federation
MeSH terms
Cardiovascular Diseases, Developing Countries, Diabetes Mellitus, Type 2, Glycated Hemoglobin, Humans, International Agencies, Global Health, Developed Countries, Disease Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review